Crossmark

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Crossref DOI link: https://doi.org/10.1186/s13054-022-04192-w

Published Online: 2022-12-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kollef, Marin H.

Timsit, Jean-François

Martin-Loeches, Ignacio

Wunderink, Richard G.

Huntington, Jennifer A.

Jensen, Erin H.

Yu, Brian

Bruno, Christopher J.
Funding

Funding for this research was provided by:

Merck Sharp and Dohme
License Information

Text and Data Mining valid from 2022-12-01

Version of Record valid from 2022-12-01
More Information

Article History

Received: 8 July 2022

Accepted: 10 October 2022

First Online: 1 December 2022

Declarations

:

: The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All participants, or their legal representatives, had to provide written informed consent in order to be eligible for participation in the study.

: Not applicable.

: MHK is a consultant for MSD and Shionogi and his efforts are supported by the Barnes-Jewish Hospital Foundation. JFT has received institutional research support from MSD. IML has received institutional research support from MSD. RGW has received institutional research support and consultancy fees from MSD. JAH, EHJ, BY, and CJB are employees of MSD, and own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.

Document is current

Any future updates will be listed below